BSE Pharma Sector Regulatory Filings — April 27, 2026

Definitive agreement to acquire Organon at $14/share, EV $11.75B, pro forma revenue $12.4B positioning top-25 global

Acquisition doubles EBITDA and cash flow, strengthens Women's Health (top-3) and biosimilars (7th largest) franchises

Combined entity spans 150 countries with 18 large markets >$100M revenue each, Organon adds 70 products in 140 countries

Board-approved deal funded by cash and bank financing, accretive post-transaction despite 2.3x Net Debt/EBITDA

NCLT Chennai approves dispensation of secured creditors' meeting due to 90.96% consent via affidavit, accelerating scheme

Composite scheme under Sections 230-232 progresses with modified meeting dates, involving Apollo Healthco, Keimed, Apollo Healthtech

Investor call recording on Organon acquisition available (April 27, 2026), pursuant to Reg 30 SEBI LODR

Merger via subsidiary enhances global scale, no forward guidance cuts noted in filings

Receipt of certified NCLT order dated April 15, 2026 on April 27 removes prior meeting hurdle

Sun's $11.75B deal dwarfs Apollo's internal restructuring in scale, signaling relative M&A outperformance

2/3 filings positive sentiment (Sun/Apollo), neutral investor call reinforces acquisition momentum

Early 2027 closure timeline provides clear forward-looking catalyst amid no insider selling disclosed

Deal closure in early 2027 subject to regulatory approvals and Organon stockholder vote, potential delays

Post-transaction Net Debt/EBITDA rises to 2.3x from financing mix of cash/bank debt

Combining portfolios across 150 countries risks execution challenges despite board approval

Upcoming unsecured creditors' meetings (May 21/26, 2026) and secured/equity (May 27) could face dissent post-90.96% consent

$14/share cash deal at $11.75B EV assumes no antitrust issues in 140+ countries

Modified dates from original May 16/17 signal procedural adjustments, IA nos. CA/CAA/8/CHE/2026 et al.

Investor call lacks new financial metrics, relying on prior acquisition details

No period-over-period trends or insider activity disclosed across 3 filings, limiting conviction signals

Reliance on bank financing amid 2.3x leverage without capex/dividend details

Multi-entity arrangement (3 companies) increases complexity under Companies Act 2013

Doubled EBITDA/cash flow from $11.75B Organon deal, trade ahead of early 2027 close

Top-25 status with $12.4B pro forma revenue, 18 markets >$100M, undervalued vs global peers

90.96% consent fast-tracks restructuring, potential synergies from Healthco/Keimed/Healthtech integration

7th largest position post-deal, alpha from segment growth without disclosed insider selling

Top-3 leadership via Organon’s 70 products, catalyst pre-closure

Equity meeting May 27, 2026 (2:30 PM) as key approval milestone

Audio review (https://sunpharma.com/...mp3) for unfiled guidance/details on FY26-27

Sun's deal signals sector consolidation, pair with Apollo restructuring for portfolio alpha

2.3x leverage post-deal remains investment-grade, room for further allocation

Unsecured meetings May 21/26 at Chennai venues, high consent momentum

Sun Pharma's $11.75B Organon acquisition (1/3 filings) drives global scale to $12.4B revenue/150 countries, implying BSE PHARMA inorganic growth trend [IMPLICATION: Buy M&A catalysts]

Apollo's NCLT-approved scheme (1/3 filings) with 90.96% consent + Sun merger signal consolidation, 2/3 filings transaction-focused [IMPLICATION: Watch approvals for unlocks]

2/3 filings positive (Sun/Apollo), neutral call reinforces; no bearish metrics across portfolio [IMPLICATION: Sector uptrend intact]

Sun's deal adds 140 countries/70 products to reach 18 markets >$100M, highlighting international alpha vs domestic focus [IMPLICATION: Favor exporters]

Sun's 2.3x post-deal Net Debt/EBITDA (no comparisons) enables doubling EBITDA, pattern for funded M&A without capex details [IMPLICATION: Monitor debt trends]

Apollo May meetings + Sun early 2027 close build event calendar, no guidance changes noted [IMPLICATION: Time entries pre-events]

Monitor regulatory/stockholder approvals for Organon acquisition, expected early 2027

Potential scheme approval, scheduled 27 May 2026 at 2:30 PM

Meeting 21 May 2026 at 11:00 AM, post-90.96% consent momentum

Meeting 26 May 2026 at 3:00 PM, Paragon Towers Chennai

27 May 2026 at 10:00 AM, final hurdle cleared via dispensation

Review April 27, 2026 recording for acquisition guidance/FY26-27 updates

Track Net Debt/EBITDA post-2.3x from financing, no prior period data

Watch for undisclosed trades/pledges in Sun/Apollo amid M&A/restructuring